I voted for the entire slate. There are too many catalysts on the near horizon that any changes could delay or jeopardize. If given no results over the next year a change will be in order. Start up biotech is difficult enough and we have a miracle drug that needs to be available. Obviously there have been several mistakes, but guess what, happens all the time even to established businesses. Nader, to me, has improved his stature in the past year and I believe he is learning to become more diplomatic. As far as income, I really don't care he's making good money if he brings the product across the line and we all make money and HAVE ACCESS to Leronlimab.